Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

The HRD score appears capable of detecting homologous recombination defects regardless of aetiology or mechanism. This score could facilitate the use of PARP inhibitors and platinum in breast, ovarian, and other cancers.